New and repurposed drugs for pediatric multidrug-resistant tuberculosis practice-based recommendations

Elizabeth P. Harausz, Anthony J. Garcia-Prats, James A. Seddon, H. Simon Schaaf, Anneke C. Hesseling, Jay Achar, Jonathan Bernheimer, Andrea T. Cruz, Lia D'Ambrosio, Anne Detjen, Stephen M. Graham, Jennifer Hughes, Sylvie Jonckheere, Ben J. Marais, Giovanni Battista Migliori, Lindsay McKenna, Alena Skrahina, Marina Tadolini, Peyton Wilson, Jennifer Furin

Research output: Contribution to journalReview articlepeer-review

60 Scopus citations


It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.

Original languageEnglish
Pages (from-to)1300-1310
Number of pages11
JournalAmerican journal of respiratory and critical care medicine
Issue number10
StatePublished - May 15 2017


  • Adolescent
  • Child
  • Multidrug-resistant tuberculosis
  • Mycobacterium tuberculosis
  • Pediatric


Dive into the research topics of 'New and repurposed drugs for pediatric multidrug-resistant tuberculosis practice-based recommendations'. Together they form a unique fingerprint.

Cite this